RxDoctor Payments Data

Somasekhara Balla, MD

Cardiovascular Disease · Greenville, NCNPI 1114098647

Payments from drug & device makers

$1,835in general payments, 2019–2025

Across 120 payments — averaging $15.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$602
  • Novartis$234
  • E.r. Squibb & Sons, L.L.C.$232
  • Johnson & Johnson$174
  • Pfizer$148
  • Irhythm Technologies, Inc.$71
  • plus $373 from 13 others

What the payments were for

  • Food & beverage$1,79998%
  • Education$362%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,835 in reported general payments places this provider in the 40th percentile of 727 cardiovascular disease providers in North Carolina.

See all cardiovascular disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$232,160
Medicare patients
1,380
Services billed
4,308

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban398$254,675
EntrestoSacubitril/Valsartan231$169,703
FarxigaDapagliflozin Propanediol122$77,260
XareltoRivaroxaban62$47,141
JardianceEmpagliflozin25$15,972
OzempicSemaglutide14$13,858
Praluent PenAlirocumab16$9,190
Metoprolol Succinate965$7,016
Repatha SureclickEvolocumab13$7,014
Isosorbide Dinitrate77$3,801
Propafenone Hcl ErPropafenone Hcl14$3,480
Isosorbide Dinit-HydralazineIsosorbide Dinit/Hydralazine17$2,342
Hydralazine Hcl257$2,073
Amlodipine Besylate643$1,979
Spironolactone445$1,953

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$148$254,675398 claims
NovartisEntresto$234$169,703231 claims
AstraZenecaFarxiga$14$77,260122 claims
Johnson & JohnsonXarelto$174$47,14162 claims
Boehringer IngelheimJardiance$46$15,97225 claims
Novo NordiskOzempic$19$13,85814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 727 cardiovascular disease providers in North Carolina.

Other cardiovascular disease in Greenville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →